

Exploring structural motifs necessary for substrate binding in the active site of *Escherichia coli* pantothenate kinase

**Dr. Emelia Awuah^a, Eric Ma^a, Annabelle Hoegl^a, Kenward Vong^a, Eric Habib^a, and Prof.
Karine Auclair^{a,*}**


^aDepartment of Chemistry, McGill University, 801 Sherbrooke Street West,
Montréal, Québec, Canada, H3A 0B8

^{*}To whom correspondence should be addressed: Karine Auclair, Department of Chemistry,
McGill University, 801 Sherbrooke Street West, Montréal, Québec, Canada, H3A 0B8, Tel:
(+1)514-398-2822; Fax: (+1)514-398-3797; Email: karine.auclair@mcgill.ca

Keywords: enzyme ligand; kinase; coenzyme A; structure-activity relationship; inhibitor,
substrate selectivity

Table of Content Graphics and Text

The promiscuity of *E. coli* PanK has limits! We report the synthesis of pantothenate analogs diversified at the β -alanine moiety, the carboxylate or the geminal dimethyl group. Interestingly, some of these are among the best substrates reported for *E. coli* PanK.



ABSTRACT

The coenzyme A (CoA) biosynthetic enzymes have been used to produce various CoA analogues, including mechanistic probes of CoA-dependent enzymes such as those involved in fatty acid biosynthesis. These enzymes are also important for the activation of the pantothenamide class of antibacterial agents, and of a recently reported family of antibiotic resistance inhibitors. Herein we report a study on the selectivity of pantothenate kinase, the first and rate limiting step of CoA biosynthesis. A robust synthetic route was developed to allow rapid access to a small library of pantothenate analogs diversified at the β -alanine moiety, the carboxylate or the geminal dimethyl group. All derivatives were tested as substrates of *Escherichia coli* pantothenate kinase (*EcPanK*). Four derivatives, all *N*-aromatic pantothenamides, proved to be equivalent to the benchmark *N*-pentylpantothenamide (N5-pan) as substrates of *EcPanK*, while two others, also with *N*-aromatic groups, were some of the best substrates reported for this enzyme. This collection of data provides insight for the future design of PanK substrates in the production of useful CoA analogues.

1. Introduction

The biosynthesis of coenzyme A (CoA),^a an essential cofactor, is a process that is ubiquitously present in all living organisms. It is most commonly a five-step process from pantothenate (vitamin B₅). Pantothenate kinase (PanK, EC 2.7.1.33) is the first and rate-limiting step of this process and is characterized by the ATP-dependent transformation of pantothenate to phosphopantothenate,¹ as shown in Fig. 1. Three main types of PanK have been identified, namely Types I, II and III, based on differences in structural fold, regulation, substrate affinity, and specificity.² Type I PanK enzymes, typically associated with bacteria, have gained significant interest due to the low sequence similarity to their human counterparts.³ Their structural and amino acid sequence similarity is considered high (52-91% similarity), with many predicted active site residues conserved among all isoforms (Fig. S1). Numerous studies have focused on developing PanK inhibitors and substrates.⁴ Of these, pantothenamides are particularly interesting due to their antibacterial activity against *S. aureus* and *E. coli*.⁵⁻¹⁰ Although the bacteriostatic effect of pantothenamides has been recognized since the 1950s, their exact mechanism of action in bacteria has only been clarified in the last 15 years.⁵⁻¹⁵ Interestingly, pantothenamides are substrates of *E. coli* PanK (*EcPanK*). Their lethal effect on bacteria stems, at least in part, from their biotransformation by the CoA biosynthetic pathway into the corresponding CoA analogues. The resulting antimetabolite proceeds to inhibit downstream pathways, such as fatty acid biosynthesis.^{8,16} Other studies have suggested that pantothenamides may, in some strains, act as inhibitors of the CoA biosynthetic pathway.^{5,16}

^aAbbreviations: CoA, coenzyme A; PanK, pantothenate kinase; *EcPanK*, PanK isoform from *Escherichia coli*; *MtPanK*, PanK isoform from *Mycobacterium tuberculosis*; *CbPanK*, PanK isoform from *Coxiella burnetii*; and *KpPanK*, PanK isoform from *Klebsiella pneumonia*.




Figure 1. Reaction scheme for the PanK-catalyzed phosphorylation of pantothenate to phosphopantthenate.

The importance of CoA analogues not only stems from their antibacterial activity, but also from their demonstrated use as chemical biology tools and as mechanistic probes of CoA-dependent enzymes. These applications include both *in vitro* and in-cell labelling of carrier proteins in polyketide and nonribosomal peptide synthesis,¹⁷⁻¹⁹ as well as aminoglycoside resistance inhibitors activated by the CoA biosynthetic pathway.²⁰

Although a wide range of pantothenamide derivatives have been reported over the years, most of these derivatives are modified at the amine moiety and less is known about the effects of modifications at other positions. Given the current and potential utility of pantothenate derivatives, a greater understanding of their effect on PanK is beneficial to future chemical biology and medicinal chemistry research. We report here on the synthesis of a library of pantothenate analogues modified at the β -alanine, the carboxylate or the geminal dimethyl group (Fig.2), and on their structure-activity relationships as *EcPanK* substrates.





Figure 2. Pantothenate analogues described in this work.

2. Results

2.1 Design and synthesis

Compounds 4-12. Compounds **4-12** are designed to probe the hydrogen bonds bridging residues Asn282 and Tyr240 to the C-7 carbonyl group of pantothenate in *EcPanK*. Their importance was suggested by studies with CoA analogues used for carrier protein labelling studies, where C-7 carbonyl group substitutions often showed detrimental effects.¹⁸ Synthesis of **4** and **5** (Scheme 1A) began with first obtaining the amine required for *D*-pantolactone ring opening. Coupling of 1-pentylamine (**13**) with Boc-glycine yielded **14**, which was coupled with Boc- β -alanine to form the Boc protected amine **15**. For the preparation of **5**, the reaction of **13** with chloroacetyl chloride first produced **16**, to which was added *tert*-butyl-3-aminopropylcarbamate to yield the Boc-protected amine **17**. With **15** and **17** in hand, subsequent Boc-deprotection followed by *D*-pantolactone addition afforded the desired compounds **4** and **5**. In the synthesis of guanidine-containing **6** (Scheme 1B), *N,N'*-di-Boc-thiourea (**18**) was first reacted with ethylenediamine to produce **19**, followed by coupling to **20** as previously reported²¹ to yield **21**. Final Boc and PMP deprotection afforded **6**. For the *p*-chloroaniline *N*-linked guanidine-containing **7** (Scheme 1C), imidazole was first reacted with cyanogen bromide to form **22**.²² Reaction of **22** with *p*-chloroaniline generated the guanidine derivative **23**, which upon addition of Boc-protected propane-1,3-diamine yielded intermediate **24**. Boc-deprotection of **24** and *D*-pantolactone addition finally afforded **7**. The assembly of triazole-containing derivatives **8** and **9** (Scheme 1D) involved 1,3-dipolar cycloadditions with *in situ* azide formation to form intermediates **26** and **28**, respectively. Deprotection and *D*-pantolactone addition then afforded **8** and **9**. Carboxylate-containing pantothenamide **10** (Scheme 1E) was assembled by first reductive amination of 3-*N*-Boc protected 2,3-diaminopropanoic acid **29** with pentanal to afford **30**, which was needed for nucleophilic ring opening of *D*-pantolactone following Boc deprotection. Synthesis of the known sulfonate-containing **11** used commercially available taurine (after NaOH treatment and precipitation) in the nucleophilic ring opening of *D*-pantolactone to yield **11**, as previously reported.²³ Finally, compound **12** (Scheme 1F) was prepared from two subsequent amide couplings of Boc-protected ethylenediamine (**31**) with butyric acid and with Boc- β -alanine to afford **33**. Deprotection of the Boc group followed by *D*-pantolactone addition yielded **12**.




Scheme 1.

(a) Boc-glycine, EDC, HOBr, DIPEA, THF, rt, 16 h, 94%; (b) TFA, DCM, rt, 1 h; (c) Boc- β -alanine, EDC, HOBr, DIPEA, THF, rt, 16 h, 60% over 2 steps; (d) *D*-pantolactone, EtOH, TEA, 80°C, 16 h, 40% over 2 steps; (e) chloroacetyl chloride, THF, rt, 16 h, 89%; (f) *tert*-butyl 3-aminopropylcarbamate, K₂CO₃, DMF, 50°C, 16 h, 60%; (g) ethylenediamine, DMF, rt, 30 min, 82%; (h) EDC, DIPEA, HOBr, THF, rt, 16 h, 79%; (i) TFA, DCM, rt, 3 h; (j) 80% AcOH, rt, 16 h, 66% over 2 steps; (k) *p*-chloroaniline, THF, rt, 12 h, 88%; (l) Boc-propane-1,3-diamine, THF, 65°C, 24 h, 86%; (m) TFA, DCM, rt, 1 h; (n) *D*-pantolactone, EtOH, TEA, 75°C, 24 h, 59% over 2 steps; (o) 1-bromopentane, NaN₃, CuSO₄·5H₂O, sodium ascorbate, DMF, H₂O, 100°C, 16 h, 81%; (p) 1-pentyne, NaN₃, CuSO₄·5H₂O, sodium ascorbate, DMF, H₂O, 100°C, 16 h, 26%; (q) TFA, DCM, rt, 1 h; (r) *D*-pantolactone, EtOH, NEt₃, 75°C, 16 h, 14–46% over 2 steps; (s) pentanal, 1% AcOH/MeOH, rt, 5 h; (t) NaBH₄, MeOH, 0°C–rt, 1 h; (u) TFA, DCM, rt, 1 h; (v) *D*-pantolactone, EtOH, NEt₃, 75°C, 24 h, 52% over 4 steps; (w)

butyric acid, EDC, HOBr, DIPEA, THF, rt, 16 h, 53%; (x) TFA, DCM, rt, 1 h; (y) Boc- β -alanine, EDC, DMAP, DIPEA, THF, rt, 16 h, 64% over 2 steps; (z) *D*-pantolactone, EtOH, NEt₃, 75°C, 16 h, 11% over 2 steps.


Compounds 35-52. The recently reported crystal structure of *KpPanK* bound to Np-Pan (**34**) suggests that PanK substrates may interact with the enzyme via π - π interactions with nearby Tyr180 and Phe259, and potentially with Tyr240, Tyr258, and Tyr262.²⁴ As such, derivatives **35-52** were synthesized and used in this study to probe the potential of pi-pi interactions with PanK. Np-Pan (**34**) was also re-synthesized because no kinetic data were reported.²⁴ For **34**, **35-39**, **41-42**, **44-46**, and **51-52** (Scheme 2A), synthesis started with the 1,3-diol protection of commercially available pantothenate as a *p*-methoxyphenyldimethylacetal to yield **53**, followed by activation to a *N*-succinamyl pantothenic ester **54**.²⁵ The desired commercially available amines were then reacted separately with **54**, followed by dilute acidic removal of the acetal protecting group to afford the *N*-linked derivatives **34**, **35-37**, **39**, **41-42**, **45**, and **51-52** in good yield. Deactivated amines such as aniline, 4-aminopyrimidine, and 3-methylpyridin-2-amine under standard reaction conditions resulted in lower yields (10-20%) of **38**, **44**, and **46** respectively. However, under microwave irradiation at 60°C for 30 min and using HATU as the coupling agent, higher yields (82-89%) of **38**, **44**, and **46** were achieved. In our hands, previous synthetic protocols for pantothenamide analogues using diphenylphosphorylazide to activate pantothenate were found to generate diphenylphosphonic acid as a byproduct which contaminated the final product.⁷ For the synthesis of **40**, **43**, and **49-50** (Scheme 2B), Boc- β -alanine (**56**) was first coupled to the desired commercially available amine to produce **57a-d**. Subsequent deprotection followed by *D*-pantolactone addition then afforded the desired compounds **40**, **43**, and **49-50**.



Scheme 2.

(a) PMPCH(OMe)₂, CSA, DMF, rt, 16 h, 75%; (b) NHS, DCC, THF, rt, 6 h-24 h, 90%; (c) R-NH₂, DCM, rt, 16 h, 69-94%; (d) 80% AcOH, rt, 16 h, 71-94%; (e) microwave, HATU, DIPEA, DMF, 60°C, 30 min; (f) 80% AcOH, rt, 16 h, 82-89% over 2 steps; (g) R-NH₂, EDC, HOBr, DIPEA, THF, rt, 16 h, 60-98%; (h) TFA, DCM, rt, 1 h; (i) *D*-pantolactone, EtOH, NEt₃, 75°C, 16 h, 10-53% over 2 steps.


Two approaches were envisaged to assemble the triclosan derivatives **47** and **48** (Scheme 3). Synthesis of the amide-linked **47** was achieved from amine **58** which was synthesized according to a literature protocol.²⁶ Subsequent coupling of **58** to **53** afforded **59**, followed by deprotection to yield **47**. Synthesis of the ether-linked triclosan derivative **48** on the other hand began with PMP-protected *D*-pantothenol **60**,²⁵ which underwent a Mistunobu reaction with triclosan to afford **61**. PMP deprotection yielded the desired product **48**.



Scheme 3.

(a) **53**, HATU, DMF, DIPEA, 80°C, 16 h, 72%; (b) 80% AcOH, rt, 16 h, 90%; (c) triclosan, Ph₃P, DIAD, THF, rt, 24 h; (d) 80% AcOH, rt, 16 h, 50% over 2 steps.

Compound 62-67. Finally, a previous study with C-2 geminal dialkylpantothenamides suggests that they might be good PanK substrates.¹¹ Crystal structure analysis points to possible interactions of the alkyl group with a hydrophobic pocket consisting of Val97, Leu201, and Ile290. Compounds **62-67** were synthesized to probe this pocket and study consequent effects on substrate activity. Synthesis of C-2 geminal dialkylpantothenamide derivatives **62-67** was achieved by adapting a protocol previously reported by our group (Scheme 4).¹¹ The known diethyl ester **68**,¹¹ was first reacted in two successive alkylations using the method developed by Seebach and Frater²⁷ to generate derivatives **70a-f** via **69a-f**. Reduction to the triol followed by selective 1,3-diol protection, left the terminal alcohol of **71a-f** available for oxidation to the corresponding acids **72a-f**, via Dess-Martin Periodinane oxidation of the alcohol to the aldehyde followed by Pinnick oxidation. The acids **72a-f** are unstable and must be used right away. Two subsequent amide couplings then afforded the desired pantothenamides **62-67**.



Scheme 4.

(a) LDA, THF, -78°C, 15 min; (b) R₁-X, -78°C-rt, 16 h, 67-75%; (c) R₂-X, 78°C-rt, 16 h, 29-58%; (d) LAH, THF, 70°C, 16 h; (e) PMPCH(OMe)₂, CSA, DCM, rt, 4 h, 50-86% over 2 steps; (f) DMP, DCM, rt, 2 h; (g) NaClO₂, NaHPO₄, acetone, DCM, H₂O, rt, 15 min; (h) piperidine, DMF, rt, 30 min; (i) EDC, DIPEA, HOEt, THF, rt, 16 h, 42-51% over 4 steps; (j) 80% AcOH, rt, 16h, 64-81%.

2.2. Biological studies.

Following the synthesis of **4-12**, **35-52**, and **62-67**, their substrate activity with *EcPanK* was measured and the results are compiled in Table 1.

Table 1. *EcPanK* kinetic parameters.

	K_m (μM)	k_{cat} (s ⁻¹)	k_{cat}/K_m (mM ⁻¹ s ⁻¹)
Pantothenate (1)			
exp	21 ± 3	1.07 ± 0.05	50 ± 7
lit ⁶	34 ± 6	0.76 ± 0.03	21 ± 2
Pantetheine (2)			
exp	60 ± 10	1.03 ± 0.06	17 ± 3
lit ¹⁷	91 ± 10	0.32 ± 0.02	3.5 ± 0.4
N5-Pan (3)			
3	36 ± 3	0.93 ± 0.04	26 ± 2
4	120 ± 10	1.12 ± 0.05	10 ± 1
5	1200 ± 400	0.13 ± 0.03	0.1 ± 0.1
6	NA ^[a]		
7	NA		
8	190 ± 20	0.96 ± 0.04	5.1 ± 0.6
9	1000 ± 200	0.49 ± 0.06	0.5 ± 0.1
10	700 ± 300	0.23 ± 0.05	0.3 ± 0.2
11	NA		
12	240 ± 30	1.09 ± 0.07	4.5 ± 0.6
34	33 ± 4	1.24 ± 0.06	38 ± 5
35	>1000	1.19 ± 0.11	0.5 ± 0.1
36	>1000	0.75 ± 0.18	0.3 ± 0.1
37	350 ± 20	1.03 ± 0.05	2.9 ± 0.3
38	43 ± 4	1.02 ± 0.05	24 ± 3
39	67 ± 6	1.15 ± 0.05	17 ± 2
40	32 ± 3	1.13 ± 0.05	35 ± 4
41	22 ± 7	0.46 ± 0.03	21 ± 6
42	50 ± 7	1.02 ± 0.05	20 ± 3
43	130 ± 30	0.94 ± 0.08	7 ± 2
44	39 ± 5	0.78 ± 0.04	20 ± 3
45	110 ± 10	1.15 ± 0.06	11 ± 1
46	450 ± 50	1.44 ± 0.09	3.2 ± 0.4
47	NA		
48	NA		
49	200 ± 100	0.45 ± 0.09	1.9 ± 0.9
50	400 ± 200	0.18 ± 0.05	0.4 ± 0.2
51	NA		
52	NA		
62	230 ± 20	1.17 ± 0.06	5.1 ± 0.5
63	1200 ± 400	0.28 ± 0.06	0.2 ± 0.1
64	590 ± 60	0.89 ± 0.06	1.5 ± 0.2
65	110 ± 10	1.04 ± 0.06	9 ± 1
66	NA		
67	NA		

^[a]NA – no observable activity up to 1 μM

While transformation of compounds **6-7**, **11**, **47-48**, **51-52**, and **66-67** by *EcPanK* is below our detection limit, complementary studies show that they did not inhibit the enzyme either (data not shown), suggesting that the compounds are likely not binding *EcPanK*. All other derivatives are substrates of *EcPanK*, yet their overall activity (k_{cat}/K_m) vary greatly from one to the other. A few compounds (**3**, **38**, **39**, **41**, **42**, **44** and **45**) show

comparable activity to that of pantetheine, while **34** and **40** are some of the rare compounds to rival the preferred substrate pantothenate.

3. Discussion

Crystal structures are reported for Type I PanK isoforms from four species: *Escherichia coli* (*EcPanK*),^{14,28} *Mycobacterium tuberculosis* (*MtPanK*),²⁹⁻³¹ *Coxiella burnetii* (*CbPanK*; PDB 3TQC), and *Klebsiella pneumoniae* (*KpPanK*).²⁴ The reported crystal structure of *EcPanK* in complex with pantothenate predicts several amino acids involved in stabilizing pantothenate binding.²⁸ These include Asp127 and His177 forming hydrogen bonds with the C1 and C3 hydroxyl groups of pantothenate, respectively; Tyr175 hydrogen bonding with the C-4 carbonyl oxygen via H₂O; and Asn282 and Tyr240 hydrogen bonding with the terminal C-7 carboxylate of pantothenate (Fig. 3A). Recently, *KpPanK* was also crystallized with **3** and **34**,²⁴ where analysis confirms similar roles of Asp127, His177, Tyr175, Asn282, and Tyr240 for substrate binding, whereas Asn282 and Tyr240 may hydrogen bond not only with the C-7 carboxylate of pantothenate but also with the C-7 amides of **3** and **34** (Fig. 3B-D). It is also interesting to note that **34** is able to adopt two different substrate conformations in the enzyme. One conformation has the pyridine moiety either positioned parallel to Tyr180 forming π-π stacking interactions (Fig. 3C), and the second conformation has the pyridine moiety positioned perpendicular to Phe259 forming T-shaped π-π interactions (Fig. 3D).




Figure 3. Highlight of the conserved active site residues involved in substrate binding; A) *EcPanK* (PDB 1SQ5) in complex with pantothenate (**1**); B) *KpPanK* (PDB 4F7W) in complex with **3**; C) *KpPanK* (PDB 4GI7) in complex with **34** (yellow) and in a conformation where sandwich π - π stacking interactions form with Tyr180, or D) *KpPanK* (PDB 4GI7) in complex with **34** (turquoise) in a conformation where T-shaped π - π interactions form with Phe259 and water-mediated hydrogen bonding between the pyridyl nitrogen and Arg243, Phe244, and Tyr240.

(PLEASE PRINT FIGURE 3 IN COLOR)

Based on the kinetic data obtained with *EcPanK* and crystal structure analysis, we were able to identify and verify several aspects of the enzyme binding pocket that are crucial for influencing the binding affinity and activity of PanK substrates. As mentioned above, the 3D structures of PanK suggest that the hydrogen bonds between the C-7 carboxylate of pantothenate and both Asn282 and Tyr240 can be sustained by an amide group

(C-7 amide of N5-Pan). This is supported by very similar K_m value (21 vs. 36 μM). The importance of the C-7 carbonyl group for binding *EcPanK* was confirmed with the 10 times difference in binding affinity between the amide-containing **4** ($k_{cat}/K_m = 10 \text{ mM}^{-1} \text{ s}^{-1}$) compared to its amide-deficient counterpart, **5** ($k_{cat}/K_m = 0.1 \text{ mM}^{-1} \text{ s}^{-1}$). This is also supported by modeling (Fig. 4A).




Figure 4. Highlight of the predicted hydrogen bonding interactions of Tyr240 and Asn282 from *EcPanK* (green) with A) **4** (yellow) and **5** (turquoise), B) **6** (turquoise) and **1** (orange), and C) **8** (yellow) and **9** (grey).

(PLEASE PRINT FIGURE 4 IN COLOR)

The next series of molecules probed whether the hydrogen bonding acceptor and donor nature of the C-7 carboxylate/amide could be mimicked with triazoles,^{32,33} guanidines, or sulfonate. The results of the kinetic studies imply that guanidine groups (as in **6** and **7**) are inadequate mimics in this context. Docking **6** into *EcPanK* suggest that the guanidine group might be better positioned near the hydroxyl group of Tyr240 (Fig. 4B). The aromatic group of **7** may however compete for Tyr240 thus preventing interaction between the guanine group of **7** and Tyr240. Triazole **8** on the other hand was a better mimic but still suffered a loss of activity ($k_{cat}/K_m = 5.1 \text{ mM}^{-1} \text{ s}^{-1}$) compared to that of **3** ($k_{cat}/K_m = 26 \text{ mM}^{-1} \text{ s}^{-1}$). Docking studies predict that hydrogen bonding with Asn282 and Tyr240 should be preserved (Fig. 4C), and hence steric effects might explain the observed loss. This hypothesis was verified with compound **9**, which has similar steric bulk as that of **8** but with a triazole moiety not positioned to hydrogen bond with Asn282 and Tyr240 (Fig. 4C). As expected **9** showed vastly reduced activity ($k_{cat}/K_m = 0.5 \text{ mM}^{-1} \text{ s}^{-1}$) compared to **8**.

Mimicking the carboxylate group was attempted with a sulfonate, however the sulfonate-containing **11** was not a substrate of PanK. A possible explanation for this observation is that the enzyme binding pocket may not tolerate the bulky tetrahedral geometry of the sulfonate group. This is further supported by the loss of activity for **10** ($k_{cat}/K_m = 0.3 \text{ mM}^{-1} \text{ s}^{-1}$), which is a derivative of pantothenate with a side chain at C-6.

Compounds **4**, **5**, and **12** were synthesized with either C-9 or C-10 amide groups. All of these compounds ($k_{cat}/K_m = 0.1-1 \text{ mM}^{-1} \text{ s}^{-1}$) displayed reduced activity compared to **3** ($k_{cat}/K_m = 26 \text{ mM}^{-1} \text{ s}^{-1}$). This is consistent with the lack of hydrogen bond acceptors/donors in the pantothenate binding pocket besides those aligned with C-7. Indeed the majority of residues in this area are hydrophobic, aromatic residues.

A recent study shows that **34** may adopt two different substrate conformations in *KpPanK*,²⁴ hinting that aromatic rings might fit better in *EcPanK*. In fact, turnover rates were better for **34** ($k_{cat}/K_m = 38 \text{ mM}^{-1} \text{ s}^{-1}$) than for **3** ($k_{cat}/K_m = 26 \text{ mM}^{-1} \text{ s}^{-1}$). Given these results, potential π - π interactions between the enzyme and substrates were probed with additional pantothenamides containing various aromatic substituents. There was little change among

binding affinities for substrates with differing chain lengths (0-3 carbons) linking the aromatic substituents to the C-7 amide, with a slight preference for 3 carbons (see **38-40**). A possible explanation for this result is that the high proportion of aromatic residues in the substrate binding pocket (e.g. Tyr180, Phe259, Tyr240, Tyr258, and Tyr262) allows a high degree of flexibility for π - π interactions to form. Overall, imidazole (e.g. **41**), pyridine (e.g. **34, 42-45**), and phenyl groups (e.g. **38-40**) were all effective for this purpose. Multi-ring aromatics (e.g. **47-48**) and bulky aromatic substituents (e.g. **49-50**), however had a detrimental effect. This suggests that the binding pocket can only accommodate one aromatic ring.

Another interesting observation with **34** was the position of the pyridyl nitrogen and its water-mediated hydrogen bonding with Tyr240, Phe244, and Arg243 of *KpPanK*.²⁴ Our studies show that the pyridyl nitrogen brings a sizable contribution (e.g. **39**, $k_{cat}/K_m = 17 \text{ mM}^{-1} \text{ s}^{-1}$), and its position matters (e.g. **42**, $k_{cat}/K_m = 20 \text{ mM}^{-1} \text{ s}^{-1}$; **43**, $k_{cat}/K_m = 7.1 \text{ mM}^{-1} \text{ s}^{-1}$). The importance of the aromatic ring was further confirmed using the amine-containing, six membered ring substituted **35**, **36**, and **37** which all showed a loss of activity with *EcPanK* ($k_{cat}/K_m = 0.3-2.9 \text{ mM}^{-1} \text{ s}^{-1}$) compared to **38-45**. As an extra control for the increase bulk of sp^3 over sp^2 hybridized carbons, the less bulky linear polyamine-containing **51** and **52** were also tested, and, as predicted they were not significantly transformed by *EcPanK*.

Analysis of the various PanK crystal structures^{14,24,28-31} reveals a cluster of residues (Val97, Leu201, and Ile290) forming a small hydrophobic pocket in the enzyme active site (Fig. 5A). To explore whether substrates can interact with this pocket via van der Waals forces, a series of **3** derivatives modified at the C-2 geminal dialkyl position were prepared. Emphasis was placed on modifying the C-2 alkyl substituent anti to the C-3 hydroxyl group, which is the position on the **3** backbone that is best suited to reach into the pocket. Of these, the propynyl derivative **65** proved to be the most promising, consistent with a previous study reporting the allyl group as the best among a variety of short alkyl groups.¹¹ A combination of reduced bulk of the propynyl substituent and stronger van der Waals forces that alkynes experience due to the increased polarity of its π -electrons as a result of its linearity, and might explain this result (Fig. 5B).




Figure 5. Highlight of the hydrophobic pocket consisting of residues Val97, Leu201, and Ile290 from *EcPanK* (green) in complex with **3** (yellow), and a modeled conformation of **65** (turquoise) and its potential reach into the hydrophobic binding pocket of *EcPanK*.

(PLEASE PRINT FIGURE 5 IN COLOR)

4. Conclusion

We have developed the synthetic route necessary to access pantothenate analogs diversified not only at the amine moiety but also at the β -alanine moiety, at the carboxylate, or at the geminal dimethyl group. Kinetic studies of these analogs with *EcPanK* revealed a number of structure-activity relationships. While some of our compounds proved to be equivalent to the benchmark compound **3**, others were some of the best substrates reported for *EcPanK*. We believe that these results will be useful to guide the future design PanK substrates for the biosynthetic generation of CoA analogues as probes or drug candidates.

EXPERIMENTAL PROCEDURES

Docking studies. Docking was performed using FITTED via the web-based platform FORECASTER.³⁴

Expression and purification of *EcPanK*. The expression vector pET28a/PanK was generously provided by Dr. Gerard D. Wright. Purification of *EcPanK* followed a protocol previously described.³⁵

Kinetic assay of EcPanK. The enzyme assay couples the production of ADP to the consumption of NADH through the activity of pyruvate kinase and lactic dehydrogenase as previously described.¹³ Reactions were performed in 96-well microtiter plates, and the decrease in NADH concentration was monitored at 340 nm every 2 seconds using a Molecular Devices Spectramax190 plate reader. Each reaction mixture (200 μ l) contained ATP (1.5 mM), NADH (0.3 mM), phosphor(enol)pyruvate (0.5 mM), MgCl₂ (10 mM), KCl (20 mM), pyruvate kinase (8 units), lactic dehydrogenase (8 units) and pantothenate kinase (1.57 μ M) in 50 mM Tris-HCl buffer (pH 7.6). The reaction was initiated with the addition of the desired substrate at variable concentrations (62.5-1000 μ M). Kinetic parameters were determined by fitting the rate data into the Michaelis-Menten equation using GraphPad Prism 4.0 with non-linear regressions. All data points are from duplicate experiments. For inhibition studies the same conditions were used but in the presence of pantothenate (1 mM) and at varying concentration (0, 0.625, 1.25, 2.5, 5, 10, and 20 mM) of the potential inhibitor.

Synthesis. Detailed synthetic protocols and compound characterizations are provided as supporting information.

ACKNOWLEDGMENTS

This work was supported by research grants from the Canadian Institute of Health Research (CIHR) and the National Science and Engineering Research Council of Canada (NSERC) to KA. CIHR provided funding as part of the Strategic Training Initiative in Chemical Biology (to K.V.), the Drug Development Training Program (to E.A. and A.H.), and a graduate scholarship (to A.H.). The Fonds québécois de la recherche sur la nature et les technologies (FQRNT, to K.V.) also provided a scholarship. The authors are grateful to G. D. Wright at McMaster University for sharing his PanK expression plasmid.

REFERENCES

- [1] W.J. Song, S. Jackowski, Cloning, sequencing, and expression of the pantothenate kinase (coA) gene of *Escherichia coli*, *J. Bacteriol.* 174 (1992) 6411-6417.
- [2] E. Strauss, Coenzyme A Biosynthesis and Enzymology, in: L. Mander, H.W. Liu (Eds.) *Comprehensive Natural Products II*, Elsevier, Oxford, 2010, pp. pg. 351-410.
- [3] S.Y. Gerdes, M.D. Scholle, M. D'Souza, A. Bernal, M.V. Baev, M. Farrell, O.V. Kurnasov, M.D. Daugherty, F. Mseeh, B.M. Polanuyer, J.W. Campbell, S. Anantha, K.Y. Shatalin, S.A.K. Chowdhury, M.Y. Fonstein, A.L.

Osterman, From genetic footprinting to antimicrobial drug targets: Examples in cofactor biosynthetic pathways, *J. Bacteriol.* 184 (2002) 4555-4572.

[4] E. Strauss, M. de Villiers, I. Rootman, Biocatalytic production of coenzyme A analogues, *ChemCatChem* 2 (2010) 929-937.

[5] K.G. Virga, Y.M. Zhang, R. Leonardi, R.A. Ivey, K. Hevener, H.W. Park, S. Jackowski, C.O. Rock, R.E. Lee, Structure-activity relationships and enzyme inhibition of pantothenamide-type pantothenate kinase inhibitors, *Bioorg. Med. Chem.* 14 (2006) 1007-1020.

[6] A.C. Mercer, J.L. Meier, G.H. Hur, A.R. Smith, M.D. Burkart, Antibiotic evaluation and in vivo analysis of alkynyl coenzyme A antimetabolites in *Escherichia coli*, *Bioorg. Med. Chem. Lett.* 18 (2008) 5991-5994.

[7] M. Van Wyk, E. Strauss, Development of a method for the parallel synthesis and purification of N-substituted pantothenamides, known inhibitors of coenzyme A biosynthesis and utilization, *Org. Biomol. Chem.* 6 (2008) 4348-4355.

[8] Y.M. Zhang, M.W. Frank, K.G. Virga, R.E. Lee, C.O. Rock, S. Jackowski, Acyl carrier protein is a cellular target for the antibacterial action of the pantothenamide class of pantothenate antimetabolites, *J. Biol. Chem.* 279 (2004) 50969-50975.

[9] G. Clifton, S.R. Bryant, C.G. Skinner, N1-(substituted) pantothenamides, antimetabolites of pantothenic acid, *Arch. Biochem. Biophys.* 137 (1970) 523-528.

[10] C. Spry, K. Kirk, K.J. Saliba, Coenzyme A biosynthesis: An antimicrobial drug target, *FEMS Microbiol. Rev.* 32 (2008) 56-106.

[11] T.O. Akinnusi, K. Vong, K. Auclair, Geminal dialkyl derivatives of N-substituted pantothenamides: synthesis and antibacterial activity, *Bioorg. Med. Chem.* 19 (2011) 2696-2706.

[12] C. Spry, C. Macuamule, Z. Lin, K.G. Virga, R.E. Lee, E. Strauss, K.J. Saliba, Pantothenamides are potent, on-target inhibitors of *Plasmodium falciparum* growth when serum pantetheinase is inactivated, *PLoS ONE* 8 (2013).

[13] E. Strauss, T.P. Begley, The antibiotic activity of N-pentylpantothenamide results from its conversion to ethyldethia-coenzyme A, a coenzyme A antimetabolite, *J. Biol. Chem.* 277 (2002) 48205-48209.

[14] M. Yun, C.G. Park, J.Y. Kim, C.O. Rock, S. Jackowski, H.W. Park, Structural basis for the feedback regulation of *Escherichia coli* pantothenate kinase by coenzyme A, *J. Biol. Chem.* 275 (2000) 28093-28099.

[15] R. Leonardi, S. Chohnan, Y.M. Zhang, K.G. Virga, R.E. Lee, C.O. Rock, S. Jackowski, A pantothenate kinase from *Staphylococcus aureus* refractory to feedback regulation by coenzyme A, *J. Biol. Chem.* 280 (2005) 3314-3322.

[16] J. Thomas, J.E. Cronan, Antibacterial activity of N-pentylpantothenamide is due to inhibition of coenzyme A synthesis, *Antimicrob. Agents Chemother.* 54 (2010) 1374-1377.

[17] A.S. Worthington, M.D. Burkart, One-pot chemo-enzymatic synthesis of reporter-modified proteins, *Org. Biomol. Chem.* 4 (2006) 44-46.

[18] J.L. Meier, A.C. Mercer, H. Rivera, M.D. Burkart, Synthesis and evaluation of bioorthogonal pantetheine analogues for in vivo protein modification, *J. Am. Chem. Soc.* 128 (2006) 12174-12184.

[19] K.M. Clarke, A.C. Mercer, J.J. La Clair, M.D. Burkart, In vivo reporter labeling of proteins via metabolic delivery of coenzyme A analogues, *J. Am. Chem. Soc.* 127 (2005) 11234-11235.

[20] K. Vong, I.S. Tam, X. Yan, K. Auclair, Inhibitors of aminoglycoside resistance activated in cells, *ACS Chem. Biol.* 7 (2012) 470-475.

[21] A.L. Mandel, J.J. La Clair, M.D. Burkart, Modular synthesis of pantetheine and phosphopantetheine, *Org. Lett.* 6 (2004) 4801-4803.

[22] Y.Q. Wu, S.K. Hamilton, D.E. Wilkinson, G.S. Hamilton, Direct synthesis of guanidines using di(imidazole-1-yl)methanimine, *J. Org. Chem.* 67 (2002) 7553-7556.

[23] E.E. Snell, A specific growth inhibition reversed by pantothenic acid *J. Biol. Chem.* 139 (1941) 975-976.

[24] B. Li, W. Tempel, D. Smil, Y. Bolshan, M. Schapira, H.W. Park, Crystal structures of *Klebsiella pneumoniae* pantothenate kinase in complex with N-substituted pantothenamides, *Proteins* 81 (2013) 1466-1472.

[25] J.D. Patrone, J. Yao, N.E. Scott, G.D. Dotson, Selective inhibitors of bacterial phosphopantothenoylcysteine synthetase, *J. Am. Chem. Soc.* 131 (2009) 16340-16341.

[26] S. Gupta, P. Babu, A. Surolia, Biphenyl ethers conjugated CdSe/ZnS core/shell quantum dots and interpretation of the mechanism of amyloid fibril disruption, *Biomaterials* 31 (2010) 6809-6822.

[27] G. Fráter, U. Müller, W. Günther, The stereoselective α -alkylation of chiral β -hydroxy esters and some applications thereof, *Tetrahedron* 40 (1984) 1269-1277.

[28] R.A. Ivey, Y.M. Zhang, K.G. Virga, K. Hevener, R.E. Lee, C.O. Rock, S. Jackowski, H.W. Park, The structure of the pantothenate kinase-ADP-pantothenate ternary complex reveals the relationship between the binding sites for substrate, allosteric regulator, and antimetabolites, *J. Biol. Chem.* 279 (2004) 35622-35629.

[29] C. Bjorkelid, T. Bergfors, A.K.V. Raichurkar, K. Mukherjee, K. Malolanarasimhan, B. Bandodkar, T.A. Jones, Structural and biochemical characterization of compounds inhibiting mycobacterium tuberculosis pantothenate kinase, *J. Biol. Chem.* 288 (2013) 18260-18270.

[30] B. Chetnani, P. Kumar, A. Surolia, M. Vijayan, M. tuberculosis pantothenate kinase: dual substrate specificity and unusual changes in ligand locations, *J. Mol. Biol.* 400 (2010) 171-185.

[31] S. Das, P. Kumar, V. Bhor, A. Surolia, M. Vijayan, Invariance and variability in bacterial PanK: A study based on the crystal structure of Mycobacterium tuberculosis PanK, *Acta Cryst. D* 62 (2006) 628-638.

[32] X. Li, Click to Join Peptides/Proteins Together, *Chem. Asian J.* 6 (2011) 2606-2616.

[33] A. Brik, J. Alexandratos, Y.C. Lin, J.H. Elder, A.J. Olson, A. Wlodawer, D.S. Goodsell, C.H. Wong, 1,2,3-triazole as a peptide surrogate in the rapid synthesis of HIV-1 protease inhibitors, *ChemBioChem* 6 (2005) 1167-1169.

[34] C.R. Corbeil, P. Englebienne, N. Moitessier, Docking ligands into flexible and solvated macromolecules. 1. Development and validation of FITTED 1.0, *J. Chem. Inf. Model.* 47 (2007) 435-449.

[35] I. Nazi, Koteva, K.P., Wright, G.D., One-pot chemoenzymatic preparation of coenzyme A analogues, *Anal. Biochem.* 324 (2004) 100-105.